北京孚博生物科技有限公司

9

手机商铺

qrcode
商家活跃:
产品热度:
  • NaN
  • 0
  • 0
  • 2
  • 2

北京孚博生物科技有限公司

入驻年限:9

  • 联系人:

    马先生

  • 所在地区:

    北京 大兴区

  • 业务范围:

    细胞库 / 细胞培养、试剂、技术服务

  • 经营模式:

    经销商 代理商

在线沟通
推荐产品

日本JCRB细胞

品牌:JCRB

$830

咨询

人皮肤组织切片(冷冻/石蜡)

品牌:Tissue Solutions

询价

询价

MCF7/182R-6

品牌:ECACC

$100

咨询

CHO-K1.Cl-0237

品牌:ECACC

$100

咨询

L929/A

品牌:ECACC

$100

咨询
查看全部产品

技术资料/正文

重组抗体定制服务

1237 人阅读发布时间:2025-01-07 15:55

传统抗体制备方法主要是依赖于动物免疫及杂交瘤细胞融合,此法存在抗体表达量偏低、且重复性较差的缺点。而利用重组抗体表达技术,无需经历免疫阶段,即可快速实现单克隆抗体的大量重复生产,降低批间差异性。

科研工作者提供抗体序列,即可通过基于哺乳动物细胞表达系统,利用自主研发的高表达载体,转染NS0/CHO/HEK293细胞,进行重组抗体生产。项目完成后最终交付≥1 mg,> 90%纯度的重组抗体。同时,也可以根据客户的批量生产要求,提供克级的高质量重组抗体。

 

孚博生物优势供应重组抗体产品,欢迎您的垂询!



服务流程:
1. 生物信息学方法分析抗体序列并预测抗体结构
2. 基因合成&亚克隆,1~2周
— 抗体结构分析及 密码子优化
— 基因合成&高表达载体构建
3. 质粒抽提,1-2周
— 转染级别质粒抽提
4. 瞬时转染表达与纯化,2-3周
— 瞬时转染
— 表达小试与检测
— 亲和纯化与多步纯化
— 质量检测QC/QA
5. 稳定细胞株筛选(可选)
— 大量及重复重组抗体生产

拥有完善成熟的哺乳动物蛋白表达平台,结合抗体测序、抗体纯化、抗体亲和力成熟等先进平台能为客户提供优质的重组抗体定制服务,包含鼠源单克隆抗体测序及表达、更换恒定区亚型的嵌合抗体表达,抗体人源化改造及表达等服务。

孚博生物可提供三百多种科研级重组药物抗体类似物,提供现货和定制服务:

adalimumab glembatumumab vedotin mirzotamab clezutoclax concizumab ustekinumab robatumumab panobacumab CAT-2200
alemtuzumab gosuranemab mitazalimab crenezumab vedolizumab romilkimab praluzatamab ravtansine CBTAU-24.1
alirocumab GSK 679586 narnatumab dapirolizumab pegol afasevikumab rontalizumab radretumab CDP571
atezolizumab GSK 933776 navicixizumab dostarlimab AGS-009 rosopatamab tetraxetan samalizumab cevostamab
avelumab ianalumab NI-0701 envafolimab AGS67E ruplizumab tarextumab Chugai SK2
basiliximab icrucumab ongericimab epratuzumab alsevalimab sabatolimab TOL101 CNTO 2125
belantamab mafodotin ieramilimab onvatilimab etrolizumab ALX-0141 sacituzumab govitecan ulocuplumab CNTO 4088
belimumab imalumab opucolimab evinacumab AMG 811 sasanlimab vandortuzumab vedotin CNTO 607
benralizumab imgatuzumab PAT-SM6 faricimab amivantamab semorinemab varlilumab CNTO5429
bevacizumab inclacumab pavurutamab farletuzumab apamistamab seribantumab vunakizumab cofetuzumab
blinatumomab indusatumab vedotin perakizumab fasinumab aprutumab setrusumab AB023 demupitamab
brentuximab vedotin iscalimab petosemtamab feladilimab ASG-5ME sevirumab AbGn-168 DISC0280
brodalumab istiratumab PF-03732010 felzartamab atinumab sifalimumab abrilumab disitamab vedotin
brolucizumab itepekimab PF-06263507 figitumumab azintuxizumab vedotin simtuzumab ABX-IL8 DLX212
burosumab itolizumab PF-06342674 fulranumab bapotulimab sonelokimab actoxumab DLX212
canakinumab ivuxolimab PG110 galiximab bepranemab sonepcizumab adecatumumab DX-2647
caplacizumab labetuzumab govitecan plamotamab ganitumab bivatuzumab mertansine talacotuzumab AGS-1C4D4 elsilimomab
cemiplimab-rwlc lacnotuzumab prasinezumab gantenerumab brontictuzumab talizumab alacizumab pegol erlizumab
certolizumab pegol lacutamab ralpancizumab gevokizumab budigalimab telazorlimab amatuximab ESBA 105
cetuximab ladiratuzumab vedotin RO5458640 girentuximab CDP484 tesidolumab AMG 714 FM101
daclizumab landogrozumab rolinsatamab talirine lampalizumab cendakimab tesnatilimab anetumab ravtansine futuximab
daratumumab lecanemab rosmantuzumab lebrikizumab cergutuzumab amunaleukin tigatuzumab anrukinzumab giloralimab
denosumab lendalizumab SAIT301 lenzilumab cibisatamab tisotumab vedotin apitegromab glofitamab
dinutuximab lifastuzumab vedotin samrotamab vedotin levilimab citatuzumab bogatox TNX-832 APX005 H2L6
dupilumab lirilumab selicrelumab ligelizumab cosibelimab tomaralimab ascrinvacumab Hersintuzumab
durvalumab loncastuximab tesirine serclutamab talirine margetuximab crotedumab tomuzotuximab astegolimab hMAK195
eculizumab lorvotuzumab mertansine sibrotuzumab mirikizumab CSL311 tovetumab avdoralimab IMC-2C5
efalizumab lulizumab pegol siplizumab mirvetuximab soravtansine cudarolimab tregalizumab balstilimab Imclone 6.64
elotuzumab lumiliximab sirtratumab vedotin motavizumab depatuxizumab trevogrumab batoclimab Immunomedics hA19
emapalumab lutikizumab sofituzumab vedotin narsoplimab dezamizumab TRU-015 befovacimab Immunomedics hA19
emicizumab LY2525623 solitomab nemolizumab DFRF4539A tusamitamab ravtansine bersanlimab indusatumab
enfortumab vedotin-ejfv marstacimab tabituximab barzuxetan netakimab dilpacimab urelumab bezlotoxumab isecarosmab
eptinezumab-jjmr matuzumab TAK-701 nimotuzumab Duke D2C7 vanucizumab BHQ880 JMW-3B3
erenumab mavrilimumab talquetamab onartuzumab dusigitumab vatelizumab bintrafusp alfa lilotomab
evolocumab miptenalimab tamrintamab pamozirine otelixizumab duvortuxizumab veltuzumab bleselumab lintuzumab satetraxetan (actinium (225Ac) )
fremanezumab-vfrm MM-111 tavolimab otilimab elezanumab vibostolimab blosozumab LK-1
galcanezumab-gnlm murlentamab teclistamab patritumab enavatuzumab vilobelimab cabiralizumab M1295
golimumab namilumab telisotuzumab ravulizumab encelimab vobarilizumab camidanlumab tesirine manelimab
guselkumab naratuximab emtansine tepoditamab retifanlimab enoblituzumab vofatamab cantuzumab mertansine mavezelimab
ibalizumab-uiyk naxitamab tibulizumab rilotumumab enoticumab volagidemab carlumab MB 311
ibritumomab tiuxetan nesvacumab tidutamab ripertamab etigilimab volociximab cinpanemab MB 311
inebilizumab-cdon NG-101 tilavonemab rovalpituzumab tesirine fianlimab vonlerizumab cixutumumab MEDI2045
infliximab NI-0801 tilvestamab rozanolixizumab flanvotumab vopratelimab cobolimab modotuximab
inotuzumab ozogamicin nipocalimab timigutuzumab satralizumab FR104 xentuzumab codrituzumab MOR-8457
ipilimumab NIS793 tinurilimab serplulimab gatipotuzumab zagotenemab coltuximab ravtansine NCI m971
isatuximab-irfc odronextamab utomilumab sirukumab gatralimab zalifrelimab crizanlizumab NCI m972
ixekizumab oleclumab vantictumab solanezumab GSK1995057 zanidatamab cusatuzumab nimacimab
lanadelumab olinvacimab vesencumab spartalizumab HuMax-IL8 zelminemab dacetuzumab NKTT320
mepolizumab olokizumab VGX100 sutimlimab icatolimab zenocutuzumab dalotuzumab nurulimab
mogamulizumab-kpkc omburtamab vibecotamab tabalumab idactamab ziltivekimab dectrekumab orilanolimab
moxetumomab pasudotox ontamalimab vorsetuzumab tanezumab ifabotuzumab zuberitamab demcizumab ORY012
natalizumab ontuxizumab vulinacimab teplizumab iladatuzumab vedotin abagovomab denintuzumab mafodotin OST 577
necitumumab opicinumab zanidatamab zovodotin tezepelumab IMA-026 abituzumab derlotuximab biotin - iodine (131I) pasotuxizumab
nivolumab oportuzumab monatox ASK8007 tiragolumab imaprelimab bimagrumab domagrozumab PDL241
obinutuzumab orticumab avizakimab tislelizumab IMC-EB10 gancotamab donanemab prolgolimab
ocrelizumab osocimab benufutamab tralokinumab IMGN779 leronlimab drozitumab quavonlimab
ofatumumab otlertuzumab bexmarilimab tremelimumab IMMU-114 naptumomab estafenatox duligotuzumab ragifilimab
olaratumab oxelumab BMS-986148 ublituximab izuralimab roledumab eldelumab ravagalimab
omalizumab ozanezumab BMS-986178 vadastuximab talirine KHK2866 visilizumab emactuzumab remtolumab
palivizumab pamrevlumab cetrelimab zalutumumab laprituximab emtansine adebrelimab EMD 273063 revdofilimab
panitumumab parsatuzumab conatumumab zanolimumab lexatumumab aducanumab emibetuzumab RG6125
pembrolizumab pateclizumab crovalimab zolbetuximab lodapolimab AMG 386 enibarcimab sapelizumab
pertuzumab pepinemab efungumab 7A7 lodelcizumab andecaliximab enokizumab SAR252067
polatuzumab vedotin-piiq pidilizumab enapotamab vedotin AB-25E9 losatuxizumab vedotin anifrolumab ensituximab setoxaximab
ramucirumab pimurutamab epcoritamab abelacimab lumretuzumab bapineuzumab etaracizumab spesolimab
ranibizumab pinatuzumab vedotin glenzocimab abrezekimab lupartumab amadotin bavituximab etokimab sugemalimab
risankizumab placulumab indatuximab ravtansine ABT-325 LY2787106 begelomab ezabenlimab tadocizumab
rituximab plozalizumab intetumumab adalimumab beta LY2928057 bemarituzumab fezakinumab tafolecimab
romosozumab-aqqg ponezumab labetuzumab APX007 LY3022855 bermekimab ficlatuzumab tebotelimab
sarilumab pozelimab letolizumab AR20.5 LY3022856 bimekizumab fletikumab tenatumomab
secukinumab prezalumab lucatumumab AS2886401-00 LY3022859 birtamimab flotetuzumab tilogotamab
siltuximab pritoxaximab magrolimab AT001 LY3076226 bococizumab fontolizumab TRX1
sintilimab quetmolimab mezagitamab ATN-658 MEDI 5117 brazikumab foralumab upifitamab
tafasitamab-cxix quilizumab milatuzumab axatilimab MEDI3617 briakinumab foravirumab urabrelimab
teprotumumab-trbw racotumomab monalizumab BAY 1158061 MEDI-547 camrelizumab fresolimumab varisacumab
tildrakizumab-asmn rafivirumab mosunetuzumab BMS-986012 MEDI-570 carotuximab frovocimab VB1-050
tocilizumab refanezumab nidanilimab BT-063 MEDI-578 clazakizumab garadacimab vixarelimab
toripalimab relatlimab ocaratuzumab C705 MINT1526A clivatuzumab tetraxetan garetosmab zampilimab
trastuzumab RG7652 ozoralizumab C836     gimsilumab  
trastuzumab emtansine rinucumab pacmilimab cantuzumab ravtansine        
资料格式:

pic 1 流程图.png

查看详细文档

上一篇

Adamas nano 纳米颗粒产品简介2

下一篇

JCRB #JCRB1018,HMY-1淋巴结黑色素瘤细胞COA

我的询价